OptiNose (OPTN) Competitors

OptiNose (NASDAQ:OPTN) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Is OPTN or ORGO more profitable?

Organogenesis has a net margin of -1.62% compared to OptiNose's net margin of -41.16%. OptiNose's return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptiNose	-41.16%	N/A	-27.42%
Organogenesis	-1.62%	-2.69%	-1.63%

Does the media prefer OPTN or ORGO?

In the previous week, OptiNose had 4 more articles in the media than Organogenesis. MarketBeat recorded 10 mentions for OptiNose and 6 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.62 beat OptiNose's score of 0.40 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptiNose	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has better valuation & earnings, OPTN or ORGO?

Organogenesis has higher revenue and earnings than OptiNose. Organogenesis is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptiNose	$78.23M	1.25	-$35.48M	-$3.00	-3.22
Organogenesis	$458.76M	0.83	$4.95M	-$0.17	-17.71

Which has more volatility and risk, OPTN or ORGO?

OptiNose has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of OPTN or ORGO?

85.6% of OptiNose shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 2.3% of OptiNose shares are owned by insiders. Comparatively, 36.9% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts rate OPTN or ORGO?

OptiNose presently has a consensus price target of $9.00, suggesting a potential downside of 6.97%. Organogenesis has a consensus price target of $5.50, suggesting a potential upside of 82.72%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than OptiNose.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptiNose	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer OPTN or ORGO?

OptiNose received 152 more outperform votes than Organogenesis when rated by MarketBeat users. However, 65.99% of users gave Organogenesis an outperform vote while only 62.88% of users gave OptiNose an outperform vote.

Company	Underperform	Outperform
OptiNose	Outperform Votes 249 62.88%	Underperform Votes 147 37.12%
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%

Summary

Organogenesis beats OptiNose on 12 of the 18 factors compared between the two stocks.